Monitor cash runway closely — $7.9M in cash provides limited funding for the planned DUBLIN-4 confirmatory Phase 3 trial. The SEED Therapeutics discontinued operations segment swung to a loss, and the prior $35.4M SEED share sale proceeds appear largely consumed. Any financing announcement or partnership deal for Plinabulin would be a significant catalyst.
Price Chart
Executive Summary
BeyondSpring reported Q1 2026 financial results with a net loss from continuing operations of $2.4M, slightly improved from a $2.6M loss in Q1 2025. The pre-revenue clinical-stage biopharma highlighted AACR 2026 preclinical data positioning Plinabulin as a potential backbone ADC combination agent and SEED Therapeutics' advancement of ST-01156 into Phase 1. Cash burn continues with cash and short-term investments declining to $7.9M from $12.6M at year-end 2025, raising financing runway concerns for a $57M market cap company.
Key Financial Metrics
Key Facts
- Net loss from continuing operations was $2.4M for Q1 2026 vs $2.6M in Q1 2025
- Cash, cash equivalents, and short-term investments fell to $7.9M as of March 31, 2026 from $12.6M at December 31, 2025
- R&D expenses increased to $1.1M from $0.9M year-over-year
- G&A expenses decreased to $1.1M from $1.7M year-over-year
- Discontinued operations (SEED Therapeutics) swung to a $4.3M net loss from $3.8M net income in Q1 2025
- AACR 2026 preclinical data showed Plinabulin enhanced ADC efficacy and tolerability in combination regimens
- SEED Therapeutics completed first dose cohort for ST-01156 Phase 1a RBM39 degrader trial
- No revenue reported for continuing operations
Financial Impact
Cash burn of ~$4.7M in Q1 2026 (continuing ops net loss + discontinued ops net loss), with $7.9M cash runway suggesting ~5-6 quarters of funding at current burn rate
Risk Factors
- Cash runway of $7.9M may be insufficient to fund DUBLIN-4 confirmatory Phase 3 trial without additional financing
- Discontinued operations (SEED) swung to a $4.3M quarterly loss from prior-year income, increasing consolidated cash burn
- Preclinical AACR data may not translate to clinical efficacy in ongoing/planned trials
- No near-term revenue catalysts — company is pre-revenue with no approved products
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001171843-26-003344 |
| Document: f8k_051326.htm | 0001171843-26-003344 |
| Document: 0001171843-26-003344-index-headers.html | 0001171843-26-003344 |
| Document: 0001171843-26-003344-index.html | 0001171843-26-003344 |
| Document: 0001171843-26-003344.txt | 0001171843-26-003344 |
| 8-K Data (Synthetic) | 0001171843-26-003344 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 6, 2026 21d ago | 8-K | $0.6450 $0.5870 | ▼ −8.99% | ▼ −8.01% | $0.4620 (−28.37%) |
Oct 2, 2026 25d ago | 8-K | $0.7860 $0.6155 | ▲ +21.69% | ▲ +22.11% | $0.4620 (+41.22%) |
Sep 29, 2026 28d ago | 8-K | $0.7733 $0.6923 | ▼ −10.47% | ▼ −12.42% | $0.4620 (−40.26%) |
Sep 29, 2026 28d ago | 424B5 | $0.7733 $0.6923 | ▲ +10.47% | ▲ +12.42% | $0.4620 (+40.26%) |
Sep 18, 2026 5w ago | 8-K | $0.7400 $1.12 | ▼ −51.35% | ▼ −52.37% | $0.4620 (+37.57%) |
Sep 3, 2026 7w ago | DEFA14A | $0.6181 $0.7600 | ▲ +22.96% | ▲ +24.17% | $0.4620 (−25.25%) |
Aug 14, 2026 10w ago | 8-K | $0.7115 $0.7092 | ▼ −0.32% | ▲ +0.87% | $0.4620 (−35.07%) |
Aug 14, 2026 10w ago | Press Release | $0.7115 $0.7092 | ▼ −0.32% | ▲ +0.87% | $0.4620 (−35.07%) |
Jun 4, 2026 20w ago | 8-K | $1.71 $1.65 | ▼ −3.51% | ▼ −0.96% | $0.4620 (−72.98%) |
Jun 2, 2026 21w ago | Press Release | $1.70 $1.72 | ▲ +1.18% | ▲ +4.14% | $0.4620 (−72.82%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers